Monday, September 21, 2026

Bargain with the Devil? US Ally Begs Trump to Accept N.K. Nuclear Freeze Over Elimination

President Lee Jae Myung calls for a new approach to North Korea, emphasizing dialogue and military strength to deter nuclear threats.

Democratic Party’s AI Powerhouse Plan: 100,000 AI Experts and a High-Tech Data Center

The Democratic Party launches an AI Powerhouse Committee to boost the industry, proposing investments in technology and workforce.

BLACKPINK’s Jennie Unveils “Fallen Angel” EP: What to Expect from Her Latest Release?

BLACKPINK's Jennie reveals concept photos for her solo EP "Fallen Angel" on social media ahead of its release.

Jin Joong Hwang

Author's Latest

A New Era in Precision Oncology—Lunit Unveils 7 AI-Driven Cancer Studies at AACR 2025

Lunit will present AI biomarker studies at AACR 2025, focusing on rare cancers and improving treatment strategies using AI analysis.

FDA Ruling Paves Way for Pharmacy Substitution of Yuflyma for Humira

Celltrion's Yuflyma receives FDA approval for interchangeability with Humira, boosting market confidence and distribution in the U.S.

FDA Greenlights CMG’s Film-Based Schizophrenia Medication ‘Mezofy’

CMG Pharmaceutical gains FDA approval for Mezofy, a unique oral film for schizophrenia, marking a milestone for South Korean pharma.

Sandoz: Millions of Patients Denied Access to Affordable Enbrel Alternative

Sandoz has filed an antitrust lawsuit against Amgen to challenge patent practices blocking its biosimilar, Erelzi, from market entry.

Europe Moves to Ease Biosimilar Rules, Boosting Asia’s Biopharma Giants

EMA's new guidelines aim to simplify biosimilar development, boosting Samsung Bioepis and Celltrion in Europe's growing market.

Long-Acting HIV Treatment Vocabria + Rekambys Offers New Hope with Just Six Injections a Year

Long-acting HIV treatment Vocabria + Rekambys improves adherence and quality of life, reducing daily pill burden to six injections yearly.

ProGen’s PG-110 Targets Fat Loss Without Muscle Waste—Next-Gen Obesity Drug in Focus

ProGen will present non-clinical results of its obesity drug PG-110 at the ADA conference, targeting muscle preservation and weight loss.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.